Form 8-K - Current report:
SEC Accession No. 0001193125-25-140727
Filing Date
2025-06-13
Accepted
2025-06-13 16:05:26
Documents
13
Period of Report
2025-06-12
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d49208d8k.htm   iXBRL 8-K 34795
2 EX-3.1 d49208dex31.htm EX-3.1 131681
  Complete submission text file 0001193125-25-140727.txt   315269

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA howl-20250612.xsd EX-101.SCH 2860
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE howl-20250612_lab.xml EX-101.LAB 19483
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE howl-20250612_pre.xml EX-101.PRE 12160
15 EXTRACTED XBRL INSTANCE DOCUMENT d49208d8k_htm.xml XML 3979
Mailing Address 200 TALCOTT AVENUE 2ND FLOOR WATERTOWN MA 02472
Business Address 200 TALCOTT AVENUE 2ND FLOOR WATERTOWN MA 02472 617-952-0555
Werewolf Therapeutics, Inc. (Filer) CIK: 0001785530 (see all company filings)

EIN.: 823523180 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40366 | Film No.: 251046468
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)